Welcome to our dedicated page for Ultralife SEC filings (Ticker: ULBI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ultralife Corporation (ULBI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ultralife is a Delaware corporation listed on the NASDAQ Stock Market, and its filings offer detailed insight into its Battery & Energy Products and Communications Systems segments, capital structure and governance.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which present consolidated financial statements, segment revenues, gross profit, operating income or loss, and information on backlog and non-GAAP metrics such as adjusted EBITDA and adjusted EPS. These reports also reflect the impact of acquisitions, including the purchase of Electrochem Solutions, Inc., and related financing and integration costs.
Ultralife’s current reports on Form 8-K document material events such as the release of quarterly results, changes in its independent registered public accounting firm, and other significant developments. For example, 8-K filings dated August 7, 2025 and November 18, 2025 reference press releases on second and third quarter results, while an 8-K dated August 27, 2025 describes the appointment of a new independent auditor.
The company also files Form 12b-25 (NT 10-K and NT 10-Q) notifications of late filing when additional time is required to complete financial reporting, as seen in the March 7, 2025 and November 7, 2025 notices related to the integration of Electrochem’s accounting systems. On Stock Titan, AI-powered tools can help summarize these filings, highlight key changes in revenues, expenses and auditor relationships, and make it easier to understand the implications for ULBI stock without reading every line of each document.
Ultralife Corp received a Schedule 13G reporting a significant shareholder. Visionary Wealth Advisors, signed for by Chief Compliance Officer Ryan Barke, reports beneficial ownership of 1,090,207 shares of Ultralife common stock, representing 6.6% of the class as of 12/31/2025.
The filer has sole voting power over 9,000 shares, no shared voting power, no sole dispositive power, and shared dispositive power over 1,090,207 shares. The holdings are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Ultralife.
Ultralife Corp director and 10% owner Bradford T. Whitmore reported purchases of the company’s common stock in mid-December 2025.
He bought 9,530 shares on December 12, 2025 at a weighted average price of $5.6257, 14,882 shares on December 15, 2025 at $5.6621, and 28,588 shares on December 16, 2025 at $5.7026, all through Whitmore Holdings, LLC.
Following these transactions, he beneficially owned 1,235,631 Ultralife shares through Whitmore Holdings, 4,452,283 shares through Sunray I, LLC, 518,616 shares through Grace Brothers, LP, and directly held 205,915 shares of common stock.
Ultralife Corp director Janie Goddard reported buying 1,739 shares of the company's common stock on 12/15/2025 at a price of $5.75 per share, according to a Form 4 insider filing.
After this purchase, she beneficially owns 7,668 Ultralife shares held directly.
Ultralife Corp (ULBI) director share purchase reported. A company director filed a Form 4 disclosing the open-market purchase of 1,750 shares of Ultralife Corp common stock on 11/24/2025 at a price of $5.67 per share. Following this transaction, the director now beneficially owns 71,000 shares held directly. The filing notes the transaction as a purchase of non-derivative common stock and indicates it was reported by a single reporting person.
Ultralife Corp (ULBI) director and 10% owner Bradford T. Whitmore reported an open-market purchase of 53,900 shares of common stock on 11/19/2025 at a weighted average price of $4.9706 per share through Whitmore Holdings, LLC.
After this transaction, he beneficially owned 1,182,631 shares indirectly through Whitmore Holdings, 205,915 shares directly, 4,452,283 shares indirectly through Sunray I, LLC, and 518,616 shares indirectly through Grace Brothers, LP. The price range for the individual trades that made up the purchase was from $4.9425 to $5.05 per share.
Ultralife Corporation (ULBI) reported an insider share purchase by its President and CEO, who is also a director. On 11/19/2025, the executive bought a total of 2,000 shares of common stock in two open-market transactions. The purchases were made at prices of $4.943 and $4.99 per share, increasing the executive’s direct beneficial ownership to 24,874 shares after the transactions. This filing reflects the executive’s personal investment activity in Ultralife stock.
Ultralife Corporation filed a current report to announce that it has released financial results for its third quarter ended September 30, 2025. The company states that these results are presented in a press release dated November 18, 2025, which is attached as Exhibit 99.1. The filing is signed by the Chief Financial Officer and Treasurer, highlighting that this is the formal disclosure of the latest quarterly performance details through the accompanying press release.
Ultralife Corporation reported higher sales but lower profitability for the quarter ended September 30, 2025. Revenue rose to $43,371 from $35,694, driven mainly by Battery & Energy Products and the contribution from the October 2024 Electrochem acquisition. Gross margin slipped to 22.2% from 24.3%, reflecting less favorable product mix, component quality issues and lower factory throughput, leading to an operating loss of $951 and a net loss attributable to Ultralife of $1,220 versus net income of $258 a year earlier.
For the first nine months of 2025, revenue increased to $142,678 from $120,604, while net income attributable to Ultralife declined to $1,524 from $6,118, as higher interest expense and integration and restructuring costs weighed on results. Electrochem, acquired for $48,022 in cash, contributed nine‑month revenue of $23,718. To fund the deal, Ultralife entered a new credit agreement including a five‑year $55,000 term loan, with $50,937 outstanding at a 6.62% borrowing rate and all debt covenants met. Operating cash flow remained solid at $9,501, lifting cash to $9,260.
Ultralife Corporation filed a Form 12b-25 (NT 10-Q) notifying a late filing for its quarterly report for the period ended September 30, 2025. The company cites its integration of Electrochem Solutions, Inc.—acquired from Integer Holdings on October 31, 2024—as the cause, noting that Electrochem’s books and records transitioned from Integer’s systems to Ultralife’s during the third quarter of 2025.
Ultralife states it needs additional time to finalize third quarter results and allow its independent accountants to complete their review without unreasonable effort or expense. The company expects to file the Form 10-Q within the five-day extension under Rule 12b-25, no later than November 17, 2025.
Ultralife Corporation replaced its independent auditor on
FAQ
What is the current stock price of Ultralife (ULBI)?
What is the market cap of Ultralife (ULBI)?
